DSIP, Epithalon, MOTS-c—three axes of biological aging and why they're discussed together.
The peptides discussed for sleep architecture and biological aging aren't a pharmacological family in the classical sense. They don't share a receptor or a common mechanism. But they cluster together in the longevity literature because they each address a distinct age-associated decline—slow-wave sleep, pineal output, or mitochondrial peptide signaling—and researchers often run them in parallel or in sequence. Understanding the category means understanding the axes they target, not the chemistry that binds them.
DSIP: sleep architecture and the aging brain
Delta Sleep-Inducing Peptide (DSIP, NF-013) is a nine-amino-acid peptide discovered in the 1970s by Schoenenberger and colleagues, isolated from the cerebral venous blood of sleeping rabbits. The origin story is unusual—it wasn't synthesized from first principles, it was extracted from nature, suggesting that sleep regulation involves this signaling molecule. In subsequent research, DSIP was shown to shift EEG patterns toward delta-wave dominance, the hallmark of deep sleep.
The human literature on DSIP is sparse and mostly non-English. The Russian clinical literature reports improvements in sleep quality, stress resilience, and subjective recovery, with proposed mechanisms involving circadian-rhythm modulation and anti-stress signaling through neuropeptide pathways. The mechanistic depth is real but narrow—we know DSIP affects sleep architecture in rodent models, and we have clinical reports suggesting benefit, but the molecular target remains debated.
DSIP is typically used in short cycles (2–4 weeks) because the literature doesn't support long-term continuous dosing. The peptide appears to "teach" the body to generate deeper sleep, and then the benefit persists into the off-cycle. This ties back to the four-phase research cycle: DSIP is a pulse-and-observe compound, not a chronic-elevation one.
Epithalon: the pineal axis and telomerase
Epithalon (also called Epitalon or Epithalamin-derived peptide, NF-010) is a tetrapeptide: alanine-glutamic acid-aspartic acid-glycine. It was synthesized as a mimic of epithalamin, an extract from the pineal gland studied extensively in Russian gerontology literature. The proposed mechanism centers on
reactivation of telomerase expression and modulation of pineal-axis aging.
The evidence base is heavily Russian-language and mechanistically specific but limited in scope. Pre-clinical work shows that Epithalon upregulates telomerase in some cell types and extends lifespan in model organisms—a claim that would transform the field if it scaled to humans, but human data is essentially absent. Some clinical reports from Russian longevity programs describe improvements in subjective vitality and biomarkers of aging, but these come from uncontrolled observational work.
The honest framing: the theoretical mechanism is elegant, but the human validation is nearly non-existent.Epithalon sits in a zone where the mechanistic story is more developed than the outcome data. Researchers using Epithalon are engaging in a hypothesis-driven experiment, not following an evidence-based protocol.
Like DSIP, Epithalon is used in short cycles—typically 10–20 days at a time, followed by months of off-cycle, with the hypothesis that a brief signaling intervention triggers longer-lasting adaptive changes in the pineal axis. Some protocols alternate Epithalon with DSIP to address both sleep and aging dimensions simultaneously.
MOTS-c: mitochondrial peptide signaling
MOTS-c (Mitochondrial-derived Peptide c, NF-025) represents a completely different axis. It's a 16-amino-acid peptide encoded in mitochondrial DNA (one of a handful of bioactive mitochondrial peptides discovered in recent years). MOTS-c activates AMPK, the cellular energy-sensing kinase, and produces an exercise-mimetic phenotype in animal models—increased glucose utilization, improved insulin sensitivity, and metabolic flexibility.
The research question with MOTS-c is fundamentally different from DSIP or Epithalon. Those peptides target neuroendocrine axes (sleep, pineal output). MOTS-c targets cellular energetics. Some researchers use MOTS-c for its metabolic benefits independent of aging. Others include it in longevity stacks because AMPK activation and mitochondrial optimization are hallmarks of biological-aging reversal in the literature.
The human evidence base is thin—mostly animal work and a handful of clinical biomarker studies—but the mechanism is clean. MOTS-c does what the literature predicts: it activates AMPK and shifts metabolism. The question is whether these shifts produce longevity benefit in humans, which remains unproven.
Why they're discussed together (and separately)
The category of "sleep and longevity peptides" exists because longevity researchers use them in parallel frameworks: DSIP for sleep quality (which mediates much of the aging literature), Epithalon for pineal-axis signaling, and MOTS-c for metabolic optimization. A researcher might run DSIP for 4 weeks, then Epithalon for 2 weeks, then MOTS-c for 8 weeks, measuring aging biomarkers (IGF-1, fasting insulin, VO₂ max, HRV, grip strength) throughout.
But they could equally be run individually—a researcher focused on sleep architecture might use DSIP alone; a researcher focused on metabolic remodeling might use MOTS-c alone. The "category" is a convenience of organization, not a requirement of mechanism.
Cycling and measurement protocols
All three peptides are typically used in short cycles (2–4 weeks for DSIP and Epithalon, 6–8 weeks for MOTS-c), often with months of observation between cycles. The rationale is that these are signaling interventions designed to trigger adaptive changes, not chronic maintenance drugs. Once you've triggered the adaptation (deeper sleep from DSIP, pineal re-activation from Epithalon, metabolic shift from MOTS-c), continuing the peptide may offer diminishing returns.
The measurement framework from the four-phase research cycle is essential here. Define your aging endpoint before you start—fasting glucose, HRV, VO₂ max, skin elasticity, grip strength, sleep efficiency, subjective energy. Baseline for 4 weeks. Run the peptide cycle. Measure throughout and for 8 weeks post-cycle. The signal often emerges in the off-cycle, as adaptive changes consolidate.
Research-protocol implications
If your goal is sleep quality alone, DSIP is the starting point. If you're targeting a broader aging axis and want multiple mechanisms, a rotating stack (DSIP → Epithalon → MOTS-c, each for short cycles) addresses different biological systems. If your primary concern is metabolic, MOTS-c can stand alone.
Stacking all three simultaneously is theoretically appealing but makes attribution difficult—if your biomarker improves, which peptide caused it? Better to test them in sequence and document the effect of each one individually.
DSIP is NF-013. Epithalon is NF-010. MOTS-c is NF-025. They're stocked individually for researchers building custom rotation cycles and aging-endpoint studies.
